BioSyent Schedules Q1 2022 earnings release for may 18,2022

MISSISSAUGA, ONTARIO (May 10, 2022) BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting
its financial results for the three months ended March 31, 2022 on Wednesday, May 18, 2022 at 8:00am ET. A
presentation on the Company’s first quarter 2022 results by René Goehrum, BioSyent President and CEO, will also be
available on the Company’s website on the date of release.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty
pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products
that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of
patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its
community, specialty and international business units.

As of the date of this press release, the Company has 12,413,261 common shares outstanding.

For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.